A Phase 4 interventional study of Mirapex and Requip in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed at 21 sites in United States. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2014-03-14.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.
Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 12th largest by enrollment, is the only one that started in 2005, is one of 10 in phase 4, and was the 2nd registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 12 · Phase 4 10
First in 1998; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 246 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 224 across the 26 interventional studies. Of the 24 that completed or were terminated, 15 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 26 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
42 studies in Parkinson Disease by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 42 finished, 22 (52%) have results posted.
Among the 42 studies in Parkinson Disease by Boehringer Ingelheim, this one is the 13th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2005, is one of 7 in phase 4, and was the 1st registered.
Boehringer Ingelheim’s Parkinson Disease studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing pramipexole in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 42 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR versus ropinirole as monitored by comprehensive ophthalmologic assessments from baseline to the end of study at two years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis and main criteria for inclusion. Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study:
Exclusion criteria
Main criteria for exclusion. The presence of any of the following would make a patient ineligible for enrollment into the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mirapex tablets three times daily (TID) dosing according to manufacturer's guidelines
Drug: Mirapex
Requip tablets three times daily (TID) dosing according to manufacturer's guidelines
Drug: Requip
Expert Panel Overall Assessment Following 2 Years on Drug
Expert panel of ophthalmologists assessed retinal deterioration by a review of the components of the comprehensive ophthalmology assessments
Time frame: up to 2 years
Expert Panel Overall Assessment Following 1 Year on Drug
Expert panel of ophthalmologists assessed retinal deterioration by a review of the components of the comprehensive ophthalmology assessments
Time frame: up to 1 years
Hoehn and Yahr Scale at Baseline
This scale is an investigator-completed assessment of the degree of complications arising from Parkinson's disease. The scale ranges from 0 (No signs) to 5 (Bedridden)
Time frame: Baseline
Hoehn and Yahr Scale at 1 Year
This scale is an investigator-completed assessment of the degree of complications arising from Parkinson's disease. The scale ranges from 0 (No signs) to 5 (Bedridden)
Time frame: Up to 1 year
Hoehn and Yahr Scale at 2 Years
This scale is an investigator-completed assessment of the degree of complications arising from Parkinson's disease. The scale ranges from 0 (No signs) to 5 (Bedridden)
Time frame: Up to 2 years
Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at Baseline
Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
Time frame: Baseline
Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at 1 Year
Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
Time frame: 1 year
Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Change From Baseline in Total Score at 1 Year
Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
Time frame: Baseline, 1 year
Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at 2 Years
Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
Time frame: 2 years
Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Change From Baseline in Total Score at 2 Years
Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
Time frame: Baseline, 2 year
Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at Baseline
Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
Time frame: Baseline
Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at 1 Year
Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
Time frame: 1 year
Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Change From Baseline in Total Score at 1 Year
Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
Time frame: Baseline, 1 year
Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at 2 Years
Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
Time frame: 2 years
Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Change From Baseline in Total Score at 2 Years
Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
Time frame: Baseline, 2 year
Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at Baseline
This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
Time frame: Baseline
Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at 1 Year
This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
Time frame: 1 year
Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Change From Baseline in Total Score at 1 Year
This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
Time frame: Baseline, 1 year
Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at 2 Years
This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
Time frame: 2 years
Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Change From Baseline in Total Score at 2 Years
This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
Time frame: Baseline, 2 year
Clinical Abnormal Findings: Clinical Laboratory Evaluations (Biochemistry and Haematology)and Vital Signs
Clinical relevant abnormalities for clinical laboratory evaluations Biochemistry and Haematology) and Vital Signs. New abnormal findings or worsening of baseline conditions were reported.
Time frame: Screen (Baseline) and final visit (24 months)
| Milestone | Pramipexole | Ropinirole |
|---|---|---|
| Started | 121 | 125 |
| Completed | 92 | 97 |
| Not completed | 29 | 28 |
| Withdrew: Adverse event | 18 | 16 |
| Withdrew: Protocol violation | 1 | 3 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Withdrawal by subject | 6 | 6 |
| Withdrew: Other reason (not specified) | 1 | 3 |
Expert panel of ophthalmologists assessed retinal deterioration by a review of the components of the comprehensive ophthalmology assessments
| Participants | Pramipexole | Ropinirole |
|---|---|---|
| Have retinal deterioration | 34 | 33 |
| Have no retinal deterioration | 81 | 86 |
Expert panel of ophthalmologists assessed retinal deterioration by a review of the components of the comprehensive ophthalmology assessments
| Participants | Pramipexole | Ropinirole |
|---|---|---|
| Have retinal deterioration | 28 | 21 |
| Have no retinal deterioration | 87 | 98 |
This scale is an investigator-completed assessment of the degree of complications arising from Parkinson's disease. The scale ranges from 0 (No signs) to 5 (Bedridden)
| Participants | Pramipexole | Ropinirole |
|---|---|---|
| Stage 0 | 0 ± 0 | 0 ± 0 |
| Stage 1 | 28 | 23 |
| Stage 1.5 | 11 | 19 |
| Stage 2 | 71 | 71 |
| Stage 2.5 | 8 | 5 |
| Stage 3 | 3 | 7 |
| Stage 4 | 0 | 0 |
| Stage 5 | 0 | 0 |
This scale is an investigator-completed assessment of the degree of complications arising from Parkinson's disease. The scale ranges from 0 (No signs) to 5 (Bedridden)
| Participants | Pramipexole | Ropinirole |
|---|---|---|
| Stage 0 | 1 ± 1 | 1 ± 1 |
| Stage 1 | 33 | 22 |
| Stage 1.5 | 9 | 16 |
| Stage 2 | 70 | 72 |
| Stage 2.5 | 8 | 8 |
| Stage 3 | 0 | 6 |
| Stage 4 | 0 | 0 |
| Stage 5 | 0 | 0 |
This scale is an investigator-completed assessment of the degree of complications arising from Parkinson's disease. The scale ranges from 0 (No signs) to 5 (Bedridden)
| Participants | Pramipexole | Ropinirole |
|---|---|---|
| Stage 0 | 1 ± 1 | 0 ± 0 |
| Stage 1 | 27 | 23 |
| Stage 1.5 | 6 | 12 |
| Stage 2 | 74 | 73 |
| Stage 2.5 | 10 | 10 |
| Stage 3 | 3 | 7 |
| Stage 4 | 0 | 0 |
| Stage 5 | 0 | 0 |
Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
| Score on a scale | Pramipexole | Ropinirole |
|---|---|---|
| Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at Baseline | 8.0 ± 3.8 | 9.5 ± 4.7 |
Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
| Score on a scale | Pramipexole | Ropinirole |
|---|---|---|
| Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at 1 Year | 7.0 ± 4.3 | 8.4 ± 5.0 |
Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
| Score on a scale | Pramipexole | Ropinirole |
|---|---|---|
| Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Change From Baseline in Total Score at 1 Year | -1.1 ± 3.4 | -1.1 ± 3.6 |
Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
| Score on a scale | Pramipexole | Ropinirole |
|---|---|---|
| Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at 2 Years | 8.4 ± 4.6 | 9.3 ± 5.2 |
Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.
| Score on a scale | Pramipexole | Ropinirole |
|---|---|---|
| Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Change From Baseline in Total Score at 2 Years | 0.4 ± 3.7 | -0.2 ± 4.0 |
Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
| Score on a scale | Pramipexole | Ropinirole |
|---|---|---|
| Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at Baseline | 20.7 ± 9.3 | 22.4 ± 10.2 |
Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
| Score on a scale | Pramipexole | Ropinirole |
|---|---|---|
| Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at 1 Year | 17.7 ± 9.3 | 19.8 ± 10.9 |
Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
| Score on a scale | Pramipexole | Ropinirole |
|---|---|---|
| Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Change From Baseline in Total Score at 1 Year | -3.0 ± 7.2 | -2.6 ± 6.1 |
Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
| Score on a scale | Pramipexole | Ropinirole |
|---|---|---|
| Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at 2 Years | 19.7 ± 9.9 | 20.9 ± 10.3 |
Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.
| Score on a scale | Pramipexole | Ropinirole |
|---|---|---|
| Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Change From Baseline in Total Score at 2 Years | -1.0 ± 7.9 | -1.5 ± 7.7 |
This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
| Score on a scale | Pramipexole | Ropinirole |
|---|---|---|
| Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at Baseline | 28.8 ± 11.6 | 31.9 ± 13.4 |
This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
| Score on a scale | Pramipexole | Ropinirole |
|---|---|---|
| Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at 1 Year | 24.7 ± 11.8 | 28.2 ± 14.5 |
This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
| Score on a scale | Pramipexole | Ropinirole |
|---|---|---|
| Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Change From Baseline in Total Score at 1 Year | -4.1 ± 8.9 | -3.7 ± 8.2 |
This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
| Score on a scale | Pramipexole | Ropinirole |
|---|---|---|
| Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at 2 Years | 28.1 ± 12.9 | 30.2 ± 14.1 |
This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).
| Score on a scale | Pramipexole | Ropinirole |
|---|---|---|
| Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Change From Baseline in Total Score at 2 Years | -0.7 ± 10.1 | -1.7 ± 10.5 |
Clinical relevant abnormalities for clinical laboratory evaluations Biochemistry and Haematology) and Vital Signs. New abnormal findings or worsening of baseline conditions were reported.
| participants | Pramipexole | Ropinirole |
|---|---|---|
| Haematocrit - Decrease | 1 | 2 |
| Haemoglobin - Decrease | 8 | 5 |
| Eosinophils - Increase | 4 | 0 |
| Phosphate - Decrease | 0 | 2 |
| Calcium - Increase | 1 | 0 |
| Glucose - Decrease | 4 | 0 |
Collected over up to 24 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pramipexole | — | 22/121 (18.2%) | 97/121 (80.2%) |
| Ropinirole | — | 21/125 (16.8%) | 101/125 (80.8%) |
| Event | Pramipexole | Ropinirole |
|---|---|---|
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/121 | 2/125 |
| Atrial fibrillationCardiac disorders | 2/121 | 1/125 |
| Cardiac failure congestiveCardiac disorders | 2/121 | 0/125 |
| AppendicitisInfections and infestations | 2/121 | 0/125 |
| Femur fractureInjury, poisoning and procedural complications | 2/121 | 0/125 |
| Lower limb fractureInjury, poisoning and procedural complications | 2/121 | 0/125 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/121 | 2/125 |
| Coronary artery occlusionCardiac disorders | 0/121 | 2/125 |
| Chest discomfortGeneral disorders | 0/121 | 2/125 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/121 | 2/125 |
| Event | Pramipexole | Ropinirole |
|---|---|---|
| SomnolenceNervous system disorders | 53/121 | 71/125 |
| NauseaGastrointestinal disorders | 31/121 | 59/125 |
| DizzinessNervous system disorders | 27/121 | 35/125 |
| FatigueGeneral disorders | 27/121 | 25/125 |
| HeadacheNervous system disorders | 15/121 | 27/125 |
| InsomniaPsychiatric disorders | 19/121 | 27/125 |
| ConstipationGastrointestinal disorders | 18/121 | 26/125 |
| Oedema peripheralGeneral disorders | 22/121 | 18/125 |
| NasopharyngitisInfections and infestations | 17/121 | 16/125 |
| Back painMusculoskeletal and connective tissue disorders | 17/121 | 9/125 |
| Age, Continuous(years) | Pramipexole | Ropinirole | Total |
|---|---|---|---|
| Mean | 57.5 ± 9.3 | 59.1 ± 8.7 | 58.3 ± 9.0 |
| Age, Customized(Participants) | Pramipexole | Ropinirole | Total |
|---|---|---|---|
| < 50 years | 23 | 17 | 40 |
| 50 to < 65 years | 71 | 74 | 145 |
| 65 to < 75 years | 21 | 30 | 51 |
| >= 75 years | 6 | 4 | 10 |
| Sex: Female, Male(Participants) | Pramipexole | Ropinirole | Total |
|---|---|---|---|
| Female | 42 | 47 | 89 |
| Male | 79 | 78 | 157 |
| Race/Ethnicity, Customized(Participants) | Pramipexole | Ropinirole | Total |
|---|---|---|---|
| Asian | 1 | 1 | 2 |
| Black | 7 | 3 | 10 |
| White | 113 | 121 | 234 |
| Height(centimeters) | Pramipexole | Ropinirole | Total |
|---|---|---|---|
| Mean | 171.3 ± 9.2 | 171.6 ± 12.4 | 171.5 ± 10.9 |
| Weight(kilograms) | Pramipexole | Ropinirole | Total |
|---|---|---|---|
| Mean | 81.32 ± 17.64 | 82.80 ± 18.39 | 82.07 ± 18.00 |
| Duration of Parkinson's disease diagnosis(years) | Pramipexole | Ropinirole | Total |
|---|---|---|---|
| Mean | 0.97 ± 1.15 | 1.29 ± 1.70 | 1.13 ± 1.46 |
| Hoehn and Yahr stage(Participants) | Pramipexole | Ropinirole | Total |
|---|---|---|---|
| Stage 0 | 0 | 0 | 0 |
| Stage 1 | 28 | 23 | 51 |
| Stage 1.5 | 11 | 19 | 30 |
| Stage 2 | 71 | 71 | 142 |
| Stage 2.5 | 8 | 5 | 13 |
| Stage 3 | 3 | 7 | 10 |
| Stage 4 | 0 | 0 | 0 |
| Stage 5 | 0 | 0 | 0 |
1 further baseline measures are reported on the registry.
The record gives a start of Jan 2005 and a primary completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2011, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pramipexole · Ropinirole